Epstein Secrets

Vaccine Trial To Include Teens. USA Today (10/22, Weintraub, 10.31M) reports that "after months of testing its COVID-19 candidate vaccine in adults, Pfizer recently lowered the age of participation to 16, aiming to include at least 3,000 older teens." Pfizer is the "only one of the leading drug compani

ard, not the relatively low bar used this year for emergency use authorization for treatments." Calling the meeting "an usual step," the AE (10/22, Neergaard, Perrone) reports Dr. Marion Gruber, director of FDA's vaccine research office, told the advisers that public scrutiny "is critical to build trust

e not going to do it that way, what we will do simultaneous development of the whole process,' and be ready so that if that vaccine from Novavax or Pfizer is ready to go, we would have tremendous bandwidth to manufacture at scale." Global Alliance Says Vaccine Should Cost No More Than $40 Per Shot. Re

traub, 10.31M), the Washington Times <https://www.washingtontimes.corn/news/2020/jul/27/virus-vaccine-put-to-final-test-in-thousands-of-vo/> (7/27, Neergaard, 492K), CQ Roll Call <https://www.rollcall.corn/2020/07/27/covid-19-vaccine-trial-update- novembed> (7/27, Siddons, 154K) and New York Times <https:

al-trials-pfizer- cincinnati/3709031001/> (10/22, Weintraub, 10.31M) reports that "after months of testing its COVID-19 candidate vaccine in adults, Pfizer recently lowered the age of participation to 16, aiming to include at least 3,000 older teens." Pfizer is the "only one of the leading drug companie

for treatments." Calling the meeting "an usual step," the AP <https://apnews.corn/article/virus-outbreak- e49203f5c55ba593ca587a56d0116b97> (10/22, Neergaard, Perrone) reports Dr. Marion Gruber, director of FDA's vaccine research office, told the advisers that public scrutiny "is critical to build trust a

Vaccine Trial To Include Teens. USA Today (10/22, Weintraub, 10.31M) reports that "after months of testing its COVID-19 candidate vaccine in adults, Pfizer recently lowered the age of participation to 16, aiming to include at least 3,000 older teens." Pfizer is the "only one of the leading drug compani

ard, not the relatively low bar used this year for emergency use authorization for treatments." Calling the meeting "an usual step," the AP (10/22, Neergaard, Perrone) reports Dr. Marion Gruber, director of FDA's vaccine research office, told the advisers that public scrutiny "is critical to build trust

re not going to do it that way, what we will do simultaneous development of the whole process,' and be ready so that if that vaccine from Novavax or Pfizer is ready to go, we would have tremendous bandwidth to manufacture at scale." Global Alliance Says Vaccine Should Cost No More Than $40 Per Shot. Re

promise, mRNA technology has never been used to make a successful vaccine before." USA Today (7/27, Weintraub, 10.31M), the Washington Times (7/27, Neergaard, 492K), CQ Roll Call (7/27, Siddons, 154K) and New York Times (7/27, Grady, 18.61M), among other news outlets, also report the story. EFTA0015040

re not going to do it that way, what we will do simultaneous development of the whole process,' and be ready so that if that vaccine from Novavax or Pfizer is ready to go, we would have tremendous bandwidth to manufacture at scale." Global Alliance Says Vaccine Should Cost No More Than $40 Per Shot. Re

promise, mRNA technology has never been used to make a successful vaccine before." USA Today (7/27, Weintraub, 10.31M), the Washington Times (7/27, Neergaard, 492K), CQ Roll Call (7/27, Siddons, 154K) and New York Times (7/27, Grady, 18.61M), among other news outlets, also report the story. CNBC (7/27,